NVAXNovavax, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$186M-37.6% YoY

Gross Profit

-$85M-45.8% margin

Operating Income

-$483M-259.8% margin

Net Income

-$510M-274.6% margin

EPS (Diluted)

$-6.53

QoQ Revenue Growth

-69.3%

Cash Flow

Operating Cash Flow

-$171M

Free Cash Flow

-$195M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$3.0B

Stockholders' Equity

-$417M

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$186M	$298M	-37.6%
Gross Profit	-$85M	$298M	-128.6%
Operating Income	-$483M	-$346M	-39.7%
Net Income	-$510M	-$352M	-44.9%

Revenue Segments

Grant

$108M58%

Product

$55M30%

Royalties and Other

$23M12%

NVAX Q2 2022 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena